Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Evaluating PARP-1 Activity Using 18F-FluorThanatrace PET/CT Scans in Patients with Pancreatic Adenocarcinoma

Trial Status: administratively complete

This pilot, early phase I trial studies how well 18F-FluorThanatrace positron emission tomography/computed tomography (PET/CT) scans work before and after treatment in identifying PARP-1 activity in patients with pancreatic adenocarcinoma. PARP-1 is a type of enzyme (protein) that helps with different functions of cells, including growth, cell death, recognizing deoxyribonucleic acid (DNA) damage, and DNA repair. 18F-FluorThanatrace is a type of drug called a radioactive tracer that is injected into the body to trace PARP-1 activity in a tumor during an imaging study. 18F-FluorThanatrace PET/CT scans may help researchers understand how PARP-1 functions as well as determine the best way to use imaging to study treatments that target PARP-1.